A Study of Necitumumab and Chemotherapy in Participants With Stage IV Squamous Non-Small Cell Lung Cancer

Squamous Non Small Cell Lung Cancer Clinical Trial

Official title:
A Randomized, Multicenter, Open-Label, Phase 2 Study of Paclitaxel-Carboplatin Chemotherapy Plus Necitumumab (IMC-11F8) Versus Paclitaxel-Carboplatin Chemotherapy Alone in the First-Line Treatment of Patients With Stage IV Squamous Non-Small Cell Lung Cancer (NSCLC)

Status Completed

Clinical Trial Summary

The main purpose of this study is to evaluate if necitumumab added to standard chemotherapy of paclitaxel and carboplatin is more effective to treat cancer than the standard chemotherapy of paclitaxel and carboplatin alone.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Carcinoma, Non-Small-Cell Lung
Lung Neoplasms
Squamous Non Small Cell Lung Cancer

Clinical Trial Details

NCT number	NCT01769391
Study type	Interventional
Source	Eli Lilly and Company
Contact
Status	Completed
Phase	Phase 2
Start date	January 2013
Completion date	July 2017

View Details

See also
Status	Clinical Trial	Phase
Active, not recruiting	`NCT04262856` - Study to Evaluate Monotherapy and Combination Immunotherapies in Participants With PD-L1 Positive Non-small Cell Lung Cancer	Phase 2
Active, not recruiting	`NCT04736173` - Study Comparing the Combination Domvanalimab and Zimberelimab With Pembrolizumab in Untreated Locally Advanced or Metastatic PD-L1-High Non-Small Cell Lung Cancer	Phase 3
Active, not recruiting	`NCT04033354` - A Randomized, Double-blind, Placebo Controlled Phase III Study to Investigate Efficacy and Safety of First-Line Treatment With HLX10 + Chemotherapy (Carboplatin-Nanoparticle Albumin Bound (Nab) Paclitaxel) in Patients With Stage IIIB/IIIC or IV NSCLC	Phase 3
Terminated	`NCT02403895` - AZD2014 and Weekly Paclitaxel in Squamous NSCLC	Phase 2